Tags : Large B-Cell

$Kite Reports Results of Yescarta (axicabtagene ciloleucel) in ZUMA-1 trial for Refractory Large B-Cell, Lymphoma, Presented at ASH 2018$

Biotech

Kite Reports Results of Yescarta (axicabtagene ciloleucel) in ZUMA-1 trial

Vartika Singh December 4, 2018

Shots: The ZUMA-1 trial involves assessing of Yescarta in patients with refractory large B-cell lymphoma for a duration of two years ZUMA-1 trial results (N=101): OR 83%; CR 58%; median […]readmore

Tags : Large B-Cell

Kite Reports Results of Yescarta (axicabtagene ciloleucel) in ZUMA-1 trial

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Company

Tags : Large B-Cell

Kite Reports Results of Yescarta (axicabtagene ciloleucel) in ZUMA-1 trial

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Categories

Related Topics

Company